Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-24
DOI
10.1002/jcp.27085
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France
- (2018) Camille Martin et al. mAbs
- A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line
- (2018) Meghdad Abdollahpour-Alitappeh et al. Artificial Cells Nanomedicine and Biotechnology
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
- (2016) Hongwen Li et al. CANCER BIOLOGY & THERAPY
- Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
- (2016) Andrew B. Waight et al. PLoS One
- Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
- (2015) Andres Forero-Torres et al. BLOOD
- An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
- (2014) S. J. Scales et al. MOLECULAR CANCER THERAPEUTICS
- In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
- (2014) Dowdy Jackson et al. PLoS One
- Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts
- (2014) Vincent A. DiPippo et al. PROSTATE
- Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates
- (2013) Nicholas J. Boylan et al. BIOCONJUGATE CHEMISTRY
- Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin
- (2013) Zhao Hui Li et al. INVESTIGATIONAL NEW DRUGS
- Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
- (2013) Elsa Wagner-Rousset et al. mAbs
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates
- (2012) Mauro Acchione et al. mAbs
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
- (2012) Sara A. Hurvitz et al. Therapeutic Advances in Medical Oncology
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
- (2011) Franco Dosio et al. Toxins
- Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
- (2009) H.-P. Gerber et al. BLOOD
- Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
- (2009) D. Dornan et al. BLOOD
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started